Hasan Ulusoy

Biography

 The Turkish pharma industry was late in investing in biological drug development, although biologics have been increasing their share of the global pharma market. Looking ahead, this tardiness is our first weakness, if not our Achilles’ heel. A select number of visionary Turkish companies have invested in biologicals development in the past three or four years. 

Research Interest

 In addition to cost cutting, we also focused on revenue growth in export markets. Nobel has been opening subsidiaries abroad since 2000. These investments abroad helped Nobel endure the period of decreased profitability at home. And last, we developed new marketing tools to enhance the product profitability per medical representative.